Literature DB >> 20632248

Recombinant factor IX for clinical and research use.

Paul E Monahan1, Jorge Di Paola.   

Abstract

The last significant advance in the therapy of hemophilia B was the introduction of recombinant factor IX (FIX), ensuring an advanced level of safety from potential infectious contaminants of plasma-derived clotting factors. Since that time, recombinant DNA techniques have been applied in research to elucidate the role of FIX and its functional domains within coagulation. At the same time, recombinant DNA technology has been applied to engineer an expanding spectrum of novel FIX therapies that are now being translating into clinical trials. The experience with the existing recombinant FIX product is reviewed with a focus on the novel products and the potential to improve the quality of life for individuals with hemophilia B.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20632248     DOI： 10.1055/s-0030-1255444

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN： 0094-6176            Impact factor:   4.180


  8 in total

1.  Christmas disease: diagnosis and management of a haemorrhagic diathesis following dentofacial trauma.

Authors:  Sridevi B Tamagond; Santosh I Hugar; Anil Patil; SandhyaRani Huddar
Journal:  BMJ Case Rep       Date:  2015-01-07

Review 2.  Animal models of hemophilia.

Authors:  Denise E Sabatino; Timothy C Nichols; Elizabeth Merricks; Dwight A Bellinger; Roland W Herzog; Paul E Monahan
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 3.  Proteases as therapeutics.

Authors:  Charles S Craik; Michael J Page; Edwin L Madison
Journal:  Biochem J       Date:  2011-04-01       Impact factor: 3.857

Review 4.  Towards personalised therapy for von Willebrand disease: a future role for recombinant products.

Authors:  Emmanuel J Favaloro
Journal:  Blood Transfus       Date:  2016-03-22       Impact factor: 3.443

5.  Treatment of hemophilia B: focus on recombinant factor IX.

Authors:  Massimo Franchini; Francesco Frattini; Silvia Crestani; Cinzia Sissa; Carlo Bonfanti
Journal:  Biologics       Date:  2013-02-12

6.  Improved expression of recombinant human factor IX by co-expression of GGCX, VKOR and furin.

Authors:  Jianming Liu; Anna Jonebring; Jonas Hagström; Ann-Christin Nyström; Ann Lövgren
Journal:  Protein J       Date:  2014-04       Impact factor: 2.371

7.  MFPred: Rapid and accurate prediction of protein-peptide recognition multispecificity using self-consistent mean field theory.

Authors:  Aliza B Rubenstein; Manasi A Pethe; Sagar D Khare
Journal:  PLoS Comput Biol       Date:  2017-06-26       Impact factor: 4.475

8.  [A phase Ⅲ multi-center clinical trial on safety and efficacy of a domestic plasma derived factor Ⅸ for the treatment of patients with hemophilia B].

Authors:  W Liu; R F Fu; Y W Zhou; Y Chen; J Yin; Z Q Yu; L H Yang; M F Wang; H Bi; Z P Zhou; X S Zhang; J L Xia; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.